Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05820100 · ClinicalTrials.gov registry record

Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT

A clinical trial of Retinitis Pigmentosa and Retinal Dystrophy, sponsored by Nanoscope Therapeutics.

Completed
Registry status
35
Enrollment target
8
Study locations

NCT05820100 is a study of Retinitis Pigmentosa and Retinal Dystrophy that has completed, run by Nanoscope Therapeutics. The registered enrollment target is 35 participants, below the 260-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (87% lower). The trial reports 8 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05820100, a study of Retinitis Pigmentosa and Retinal Dystrophy, has completed, sponsored by Nanoscope Therapeutics.

COMPLETED
Registry status
35 participants
Enrollment target
8
Study locations

Study Summary

This is a prospective Multi-Center Observational Study to assess the reliability and validity of the Multi-Luminance Y-Mobility Test (MLYMT) and Multi-Luminance Shape Discrimination Study (MLSDT) Main Outcome Measures: (i) Performance scores in normal and severely visually impaired subjects with a clinical diagnosis of retinitis pigmentosa (RP) on MLYMT and MLSDT at multiple luminance levels and (ii) reliability and content validity of MLYMT and MLSDT.

Conditions Studied

Retinitis Pigmentosa Retinal Dystrophy

Interventions

  • OTHER Observational

Study Locations (8)

Texas

  • Nanoscope Clinical Site - Bellaire
  • Nanoscope Clinical Site - McAllen
  • Nanoscope Clincal Site - San Antonio

Arizona

  • Nanoscope Clinical Site - Phoenix

California

  • Nanoscope Clinical Site - Beverly Hills

Florida

  • Nanoscope Clinical Site - Miami

North Dakota

  • Nanoscope Clinical Site - Fargo

Other

  • Nanoscope Clinical Site - Arecibo

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2023-04-25
Est. Completion 2023-10-17

Sponsor

Nanoscope Therapeutics

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05820100

The ClinicalTrials.gov registry entry for NCT05820100 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 260-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (87% lower). The listed sponsor is Nanoscope Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 1 intervention - of which Observational is the first listed.

NCT05820100 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Texas, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT05820100 about?

NCT05820100 is a clinical study titled "Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT". This is a prospective Multi-Center Observational Study to assess the reliability and validity of the Multi-Luminance Y-Mobility Test (MLYMT) and Multi-Luminance Shape Discrimination Study (MLSDT) Main Outcome Measures: (i) Performance scores in normal and severely visually impaired subjects with a c...

What is the current status of trial NCT05820100?

This trial is currently completed. The enrollment target is 35 participants. The study started on 2023-04-25. Estimated completion is 2023-10-17.

What conditions does trial NCT05820100 study?

This clinical trial studies the following conditions: Retinitis Pigmentosa, Retinal Dystrophy.

What interventions are being tested in trial NCT05820100?

The interventions under investigation include: Observational (OTHER).

Who is sponsoring clinical trial NCT05820100?

This trial is sponsored by Nanoscope Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05820100 being conducted?

This trial has 8 study locations across Arizona, California, Florida, North Dakota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Retinitis Pigmentosa

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Retinitis Pigmentosa

All registered trials for this condition

Retinal Dystrophy

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.